CEO Bob Proulx Featured on Biotech2050 Podcast

Earlier this year Imagion Biosystems CEO Bob Proulx was invited to be a guest and record an episode of the Biotech2050 podcast. The COVID-19 pandemic delayed…


Appendix 4D and Half Year Results H1 2020

Imagion Biosystems has announced Appendix 4D and Half Year Results H1 2020. These are the highlights: Significant advancements towards initiating…


IBX Secures Additional Capital — Shareholders Exercise Options

Imagion Biosystems Limited announce that it has received $1.29m for the exercise of unlisted options issued under the terms of the 2018 Rights Issue…


Phase I Study Update: Submission for Ethics Approval Filed

Imagion Biosystems is pleased to provide an update with regard to its plans to undertake a Phase I study of its first MagSense™ product for the detection of…


Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Imagion Biosystems Limited gives notice that, on 4 August 2020 the Company issued 112,111,111 fully paid ordinary shares (Shares) as well as 6,500,000…


Quarterly Activity Report and Appendix C

Quarterly Activity Report – Period ending 30 June 2020 Q2 Highlights: Company announces plans for the Phase I first-in-human study to be undertaken in…


Proposed Issue of Securities — IBX

Imagion Biosystems Limited has announced a Proposed Issue of Securities. Read the Proposed Issue of Securities.


Proposed Issue of Securities — IBXOA

Imagion Biosystems has announced a Proposed Issue of Securities. Read the Proposed Issue of Securities.


IBX Raises $5M in Oversubscribed Placement

$5M raised in an oversubscribed placement at 4.5c per share – equivalent to 30 day VWAP, and a 33.9% premium to 60 day VWAP. Strongly supported by existing…


Appendix 2A

The application for quotation (Appendix 2A) for listed options (IBCOA) was released to the market. Read Appendix 2A.